Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc., as noted in the metadata) on November 6, 2012. The report serves to announce the Company's financial results for the quarter ended September 30, 2012, referencing a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing does not provide specific details on material changes versus the prior comparable period. It solely references the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It explicitly states that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the Press Release dated November 6, 2012 (Exhibit 99.1) referenced in this filing.
- Confirm the Company name is AcelRx Pharmaceuticals, Inc., as the metadata provided in the request incorrectly lists "TALPHERA, INC."
- Note that the financial data in this 8-K is not incorporated by reference into future filings, requiring direct review of the original press release for due diligence.